These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 6271817)

  • 1. Mechanism for national distribution of delta 9-tetrahydrocannabinol (NSC-134454).
    Abraham D; Pina KR; Davignon JP
    J Clin Pharmacol; 1981; 21(S1):122S-127S. PubMed ID: 6271817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. delta 9-Tetrahydrocannabinol and therapeutic research legislation for cancer patients.
    Treffert DA; Joranson DE
    JAMA; 1983 Mar; 249(11):1469-72. PubMed ID: 6298477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Schedules of Controlled Substances: Placement of FDA-Approved Products of Oral Solutions Containing Dronabinol [(-)-delta-9-transtetrahydrocannabinol (delta-9-THC)] in Schedule II. Interim final rule, with request for comments.
    Drug Enforcement Administration, Department of Justice
    Fed Regist; 2017 Mar; 82(55):14815-20. PubMed ID: 28355049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Schedules of Controlled Substances: Placement of FDA-Approved Products of Oral Solutions Containing Dronabinol [(-)-delta-9-trans- tetrahydrocannabinol (delta-9-THC)] in Schedule II. Final rule.
    Drug Enforcement Administration, Department of Justice.
    Fed Regist; 2017 Nov; 82(224):55504-6. PubMed ID: 29232070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The California program for the investigational use of THC and marihuana in heterogeneous populations experiencing nausea and vomiting from anticancer therapy.
    Dow GJ; Meyers FH
    J Clin Pharmacol; 1981; 21(S1):128S-132S. PubMed ID: 6271818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cannabis-based medicines--GW pharmaceuticals: high CBD, high THC, medicinal cannabis--GW pharmaceuticals, THC:CBD.
    Drugs R D; 2003; 4(5):306-9. PubMed ID: 12952500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New Drug Enforcement Administration guideline for communicating controlled substance prescriptions to pharmacies.
    Drug Enforcement Adminstration U S Department of Justice
    J Pain Palliat Care Pharmacother; 2011; 25(1):83-9. PubMed ID: 21426229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
    Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
    Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Legal format and costs of prescriptions at the Central Hospital in Yaounde, Cameroon].
    Blatt A; Chambon R; Lemardeley P
    Med Trop (Mars); 1997; 57(1):37-40. PubMed ID: 9289607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Controlled Substances Therapeutic Research Act in the state of Washington.
    Roffman RA
    J Clin Pharmacol; 1981; 21(S1):133S-140S. PubMed ID: 6271819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Schedules of controlled substances: rescheduling of the Food and Drug Administration approved product containing synthetic dronabinol [(-) - [DELTA] less than 9 greater than - (trans)-tetrahydrocannabinol] in sesame oil and encapsulated in soft gelatin capsules from schedule II to schedule III. Department of Justice (DOJ), Drug Enforcement Administration (DEA). Final rule.
    Fed Regist; 1999 Jul; 64(127):35928-30. PubMed ID: 10558581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. delta 9-tetrahydrocannabinol in clinical oncology.
    Poster DS; Penta JS; Bruno S; Macdonald JS
    JAMA; 1981 May 22-29; 245(20):2047-51. PubMed ID: 6262541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ASHP national survey of hospital-based pharmaceutical services--1994.
    Santell JP
    Am J Health Syst Pharm; 1995 Jun; 52(11):1179-98. PubMed ID: 7656108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delta-9-tetrahydrocannabinol in cancer chemotherapy: research problems and issues.
    Carey MP; Burish TG; Brenner DE
    Ann Intern Med; 1983 Jul; 99(1):106-14. PubMed ID: 6305249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tetrahydrocannabinol: from pot to prescription?
    Laszlo J
    Ann Intern Med; 1979 Dec; 91(6):916-8. PubMed ID: 517895
    [No Abstract]   [Full Text] [Related]  

  • 16. delta 9-Tetrahydrocannabinol for refractory vomiting induced by cancer chemotherapy.
    Lucas VS; Laszlo J
    JAMA; 1980 Mar; 243(12):1241-3. PubMed ID: 6244418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Guidelines for prescribers of controlled substances: a joint statement of the Drug Enforcement Administration (DEA) and the DEA/Practitioners Working Committee.
    Fed Bull; 1980 Feb; 67(2):47-50. PubMed ID: 10245393
    [No Abstract]   [Full Text] [Related]  

  • 18. How we comply with federal guidelines on THC dispensing.
    Goldstein MS; Williams FF
    Pharm Times; 1981 Oct; 47(10):32-6. PubMed ID: 10278105
    [No Abstract]   [Full Text] [Related]  

  • 19. Allowing central fill pharmacies and retail pharmacies to fill prescriptions for controlled substances on behalf of retail pharmacies. Final rule.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2003 Jun; 68(121):37405-11. PubMed ID: 12836645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenges of thalidomide distribution in a hospital setting.
    Keravich DP; Daniels CE
    Am J Health Syst Pharm; 1999 Sep; 56(17):1721-5. PubMed ID: 10512502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.